101 related articles for article (PubMed ID: 16886675)
1. Calcitriol in the treatment of prostate cancer.
Beer TM; Myrthue A
Anticancer Res; 2006; 26(4A):2647-51. PubMed ID: 16886675
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer.
Beer TM; Javle M; Lam GN; Henner WD; Wong A; Trump DL
Clin Cancer Res; 2005 Nov; 11(21):7794-9. PubMed ID: 16278401
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
Trump DL; Muindi J; Fakih M; Yu WD; Johnson CS
Anticancer Res; 2006; 26(4A):2551-6. PubMed ID: 16886663
[TBL] [Abstract][Full Text] [Related]
4. ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
Beer TM
BJU Int; 2005 Sep; 96(4):508-13. PubMed ID: 16104901
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.
Beer TM; Javle MM; Ryan CW; Garzotto M; Lam GN; Wong A; Henner WD; Johnson CS; Trump DL
Cancer Chemother Pharmacol; 2007 Apr; 59(5):581-7. PubMed ID: 17066293
[TBL] [Abstract][Full Text] [Related]
6. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation.
Beer TM; Munar M; Henner WD
Cancer; 2001 Jun; 91(12):2431-9. PubMed ID: 11413535
[TBL] [Abstract][Full Text] [Related]
7. Development of weekly high-dose calcitriol based therapy for prostate cancer.
Beer TM
Urol Oncol; 2003; 21(5):399-405. PubMed ID: 14670552
[TBL] [Abstract][Full Text] [Related]
8. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy.
Smith DC; Johnson CS; Freeman CC; Muindi J; Wilson JW; Trump DL
Clin Cancer Res; 1999 Jun; 5(6):1339-45. PubMed ID: 10389917
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.
Muindi JR; Potter DM; Peng Y; Johnson CS; Trump DL
Cancer Chemother Pharmacol; 2005 Nov; 56(5):492-6. PubMed ID: 15918041
[TBL] [Abstract][Full Text] [Related]
10. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
Beer TM; Myrthue A; Eilers KM
World J Urol; 2005 Feb; 23(1):28-32. PubMed ID: 15668801
[TBL] [Abstract][Full Text] [Related]
11. RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.
Yin Y; Ni J; Chen M; Guo Y; Yeh S
Clin Cancer Res; 2009 Jan; 15(1):190-200. PubMed ID: 19118046
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor activity of calcitriol: pre-clinical and clinical studies.
Trump DL; Hershberger PA; Bernardi RJ; Ahmed S; Muindi J; Fakih M; Yu WD; Johnson CS
J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):519-26. PubMed ID: 15225831
[TBL] [Abstract][Full Text] [Related]
13. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Beer TM; Hough KM; Garzotto M; Lowe BA; Henner WD
Semin Oncol; 2001 Aug; 28(4 Suppl 15):49-55. PubMed ID: 11685729
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
15. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of calcitriol and naproxen in recurrent prostate cancer.
Srinivas S; Feldman D
Anticancer Res; 2009 Sep; 29(9):3605-10. PubMed ID: 19667155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
